Phenytoin-associated thrombocytopenia in a toddler

Area of Science:

• Pediatric Hematology
• Pharmacovigilance
• Adverse Drug Reactions

Background:

• Phenytoin is an anticonvulsant medication.
• Hematologic side effects, including thrombocytopenia, are rare but documented adverse events associated with phenytoin therapy.
• Thrombocytopenia is a condition characterized by abnormally low levels of platelets in the blood.

Observation:

• A case report of a 2-year-old female patient treated with phenytoin.
• The patient developed thrombocytopenia during the course of phenytoin treatment.
• The onset of thrombocytopenia was observed on the 11th day of therapy.

Findings:

• The patient experienced reversible thrombocytopenia, a rare hematologic side effect of phenytoin.
• This adverse event occurred earlier than typically reported in adults, developing within 11 days of therapy initiation.
• Discontinuation of phenytoin led to the resolution of thrombocytopenia within 5 days.

Implications:

• Highlights the potential for phenytoin to cause thrombocytopenia in pediatric patients.
• Suggests that the onset of phenytoin-induced thrombocytopenia may differ in children compared to adults.
• Emphasizes the importance of monitoring for hematologic changes in children receiving phenytoin therapy.